Poxel (OTCMKTS:PXXLF) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Poxel (OTCMKTS:PXXLF – Get Rating) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “

PXXLF opened at $2.10 on Wednesday. The company’s 50-day moving average is $3.49 and its 200 day moving average is $5.21. Poxel has a fifty-two week low of $2.10 and a fifty-two week high of $5.83.

Poxel Company Profile (Get Rating)

Poxel SA, a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight.

Recommended Stories